CN110637010A - 一种vegfr抑制剂晶型及其制备方法 - Google Patents

一种vegfr抑制剂晶型及其制备方法 Download PDF

Info

Publication number
CN110637010A
CN110637010A CN201880032790.8A CN201880032790A CN110637010A CN 110637010 A CN110637010 A CN 110637010A CN 201880032790 A CN201880032790 A CN 201880032790A CN 110637010 A CN110637010 A CN 110637010A
Authority
CN
China
Prior art keywords
formula
compound
theta
ray powder
error range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880032790.8A
Other languages
English (en)
Inventor
杨俊然
李俊明
王立坤
杜振兴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN110637010A publication Critical patent/CN110637010A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

提供了一种VEGFR抑制剂晶型及其制备方法。具体而言，提供了N‑[4‑(1‑氰基环戊基)苯基]‑2‑(4‑吡啶甲基)氨基‑3‑吡啶甲酰胺(式I)晶型A～J及其制备方法。

Description

PCT国内申请，说明书已公开。

Claims (30)

  1. PCT国内申请，权利要求书已公开。
CN201880032790.8A 2017-08-15 2018-08-14 一种vegfr抑制剂晶型及其制备方法 Pending CN110637010A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2017106982820 2017-08-15
CN201710698282 2017-08-15
CN201710701633 2017-08-16
CN2017107016339 2017-08-16
PCT/CN2018/100413 WO2019034048A1 (zh) 2017-08-15 2018-08-14 一种vegfr抑制剂晶型及其制备方法

Publications (1)

Publication Number Publication Date
CN110637010A true CN110637010A (zh) 2019-12-31

Family

ID=65362386

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880032790.8A Pending CN110637010A (zh) 2017-08-15 2018-08-14 一种vegfr抑制剂晶型及其制备方法

Country Status (2)

Country Link
CN (1) CN110637010A (zh)
WO (1) WO2019034048A1 (zh)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1502608A (zh) * 2002-11-27 2004-06-09 南京凯衡科贸有限公司 具有抑制血管生成活性的六员氨基酰胺类衍生物
CN101676267A (zh) * 2008-09-16 2010-03-24 江苏恒瑞医药股份有限公司 N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐
CN104086484A (zh) * 2014-07-08 2014-10-08 上海宣创生物科技有限公司 烟酰胺类衍生物的甲磺酸盐溶剂化物晶体及其制备方法和应用
CN106243031A (zh) * 2016-07-26 2016-12-21 江苏恒瑞医药股份有限公司 一种阿帕替尼的制备方法
CN108250139A (zh) * 2016-12-28 2018-07-06 上海宣创生物科技有限公司 阿帕替尼b晶型及其制备方法和应用
CN108250137A (zh) * 2016-12-28 2018-07-06 上海宣创生物科技有限公司 阿帕替尼c晶型及其制备方法和应用
CN108250138A (zh) * 2016-12-28 2018-07-06 上海宣创生物科技有限公司 阿帕替尼a晶型及其制备方法和应用
CN109020881A (zh) * 2018-06-28 2018-12-18 新发药业有限公司 一种阿帕替尼的制备方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1502608A (zh) * 2002-11-27 2004-06-09 南京凯衡科贸有限公司 具有抑制血管生成活性的六员氨基酰胺类衍生物
CN101676267A (zh) * 2008-09-16 2010-03-24 江苏恒瑞医药股份有限公司 N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐
CN104086484A (zh) * 2014-07-08 2014-10-08 上海宣创生物科技有限公司 烟酰胺类衍生物的甲磺酸盐溶剂化物晶体及其制备方法和应用
CN106243031A (zh) * 2016-07-26 2016-12-21 江苏恒瑞医药股份有限公司 一种阿帕替尼的制备方法
CN108250139A (zh) * 2016-12-28 2018-07-06 上海宣创生物科技有限公司 阿帕替尼b晶型及其制备方法和应用
CN108250137A (zh) * 2016-12-28 2018-07-06 上海宣创生物科技有限公司 阿帕替尼c晶型及其制备方法和应用
CN108250138A (zh) * 2016-12-28 2018-07-06 上海宣创生物科技有限公司 阿帕替尼a晶型及其制备方法和应用
CN109020881A (zh) * 2018-06-28 2018-12-18 新发药业有限公司 一种阿帕替尼的制备方法

Also Published As

Publication number Publication date
WO2019034048A1 (zh) 2019-02-21

Similar Documents

Publication Publication Date Title
TWI461418B (zh) 醫藥調配物
EP3125872B1 (en) Amorphous solid dispersion comprising taxane, tablet comprising the same, and method for preparing the same
CN104870443B (zh) 具有改善的溶解度的包含四唑衍生物作为活性成分的固体分散体
US11179392B2 (en) Solid pharmaceutical formulation of PARP inhibitors and use thereof
US8445502B2 (en) Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same
WO2012085927A2 (en) Tadalafil compositions
US11951100B2 (en) Formulations of RBP4 inhibitors and methods of use
EP3601265B1 (en) Solid form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol
WO2016155670A1 (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
KR20200092956A (ko) 고체 분산체
KR20230054394A (ko) 비정질 형태의 malt1 억제제 및 이의 제형
CN110637010A (zh) 一种vegfr抑制剂晶型及其制备方法
WO2015145157A1 (en) Pharmaceutical composition comprising pazopanib
WO2015121649A1 (en) Pharmaceutical composition comprising vemurafenib
US20210308116A1 (en) Solid dispersion comprising an anticancer compound for improved solubility and efficacy
KR20210146008A (ko) 메게스테롤 아세테이트를 포함하는 고체분산체 및 이의 제조방법
TWI520752B (zh) 決奈達隆固體分散體及其製備方法
CN111686081A (zh) 负载有吡啶氧化物衍生物的纳米微球及其用途
WO2009009292A2 (en) Crystalline forms of naltrexone methobromide
NZ723991B2 (en) Amorphous solid dispersion comprising taxane, tablet comprising the same, and method for preparing the same
JP2005213235A (ja) キサンチン誘導体水和物
KR20150001458A (ko) 용해도가 개선된 무정형의 드로네다론 염산염의 제조 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191231